XBiotech Inc. (NASDAQ:XBIT - Get Free Report)'s stock price passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $6.99 and traded as high as $7.65. XBiotech shares last traded at $7.39, with a volume of 62,083 shares traded.
XBiotech Stock Performance
The company's fifty day moving average is $7.01 and its two-hundred day moving average is $7.02. The company has a market cap of $221.13 million, a price-to-earnings ratio of -7.12 and a beta of 1.41.
XBiotech (NASDAQ:XBIT - Get Free Report) last issued its quarterly earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.43) earnings per share for the quarter.
Institutional Investors Weigh In On XBiotech
Hedge funds have recently bought and sold shares of the stock. Rhumbline Advisers boosted its position in XBiotech by 2,568.5% in the 2nd quarter. Rhumbline Advisers now owns 20,094 shares of the biopharmaceutical company's stock worth $103,000 after purchasing an additional 19,341 shares in the last quarter. American Century Companies Inc. purchased a new stake in XBiotech in the 2nd quarter worth approximately $393,000. Bank of New York Mellon Corp boosted its position in XBiotech by 102.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 98,314 shares of the biopharmaceutical company's stock worth $505,000 after purchasing an additional 49,863 shares in the last quarter. Empowered Funds LLC boosted its position in XBiotech by 7.9% in the 1st quarter. Empowered Funds LLC now owns 64,277 shares of the biopharmaceutical company's stock worth $523,000 after purchasing an additional 4,725 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in XBiotech by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 895,315 shares of the biopharmaceutical company's stock worth $7,279,000 after purchasing an additional 13,804 shares in the last quarter. Hedge funds and other institutional investors own 55.70% of the company's stock.
About XBiotech
(
Get Free Report)
XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.
Featured Stories
Before you consider XBiotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XBiotech wasn't on the list.
While XBiotech currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
